<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <titles>
      <item>
        <parentTitleType />
        <title>Adding Ebola to the FDA Priority Review Voucher Program Act</title>
        <titleType>Short Titles as Introduced</titleType>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <parentTitleType />
        <title>To expand the program of priority review to encourage treatments for tropical diseases.</title>
        <titleType>Official Title as Introduced</titleType>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <parentTitleType />
        <title>Adding Ebola to the FDA Priority Review Voucher Program Act</title>
        <titleType>Display Title</titleType>
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <updateDate>2016-10-25T16:17:20Z</updateDate>
    <congress>113</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>By Mrs. BLACKBURN:H.R. 5729.Congress has the power to enact this legislation pursuantto the following:The Constitutional authority in which this bill rests isthe power of the Congress to regulate Commerce as enumeratedby Article I, Section 8, Clause 3 as applied to healthcare.[Page H8071]</pre>]]></constitutionalAuthorityStatementText>
    <summaries>
      <billSummaries>
        <item>
          <text><![CDATA[<p>Adding Ebola to the FDA Priority Review Voucher Program Act - Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.)</p> <p>Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS).</p> <p>Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times.</p> Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.]]></text>
          <updateDate>2014-11-18T05:00:00Z</updateDate>
          <name>Introduced in House</name>
          <versionCode>00</versionCode>
          <actionDesc>Introduced in House</actionDesc>
          <lastSummaryUpdateDate>2014-11-25T19:46:48Z</lastSummaryUpdateDate>
          <actionDate>2014-11-18</actionDate>
        </item>
      </billSummaries>
    </summaries>
    <recordedVotes />
    <cboCostEstimates />
    <sponsors>
      <item>
        <middleName />
        <firstName>Marsha</firstName>
        <identifiers>
          <lisID>1748</lisID>
          <bioguideId>B001243</bioguideId>
          <gpoId>8154</gpoId>
        </identifiers>
        <district>7</district>
        <lastName>Blackburn</lastName>
        <fullName>Rep. Blackburn, Marsha [R-TN-7]</fullName>
        <party>R</party>
        <byRequestType />
        <bioguideId>B001243</bioguideId>
        <state>TN</state>
      </item>
    </sponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <calendarNumbers />
    <billType>HR</billType>
    <committees>
      <billCommittees>
        <item>
          <name>Energy and Commerce Committee</name>
          <type>Standing</type>
          <systemCode>hsif00</systemCode>
          <chamber>House</chamber>
          <subcommittees>
            <item>
              <systemCode>hsif14</systemCode>
              <name>Health Subcommittee</name>
              <activities>
                <item>
                  <name>Referred to</name>
                  <date>2014-11-21T21:02:55Z</date>
                </item>
              </activities>
            </item>
          </subcommittees>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2014-11-18T15:00:31Z</date>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <relatedBills>
      <item>
        <latestAction>
          <actionDate>2014-12-16</actionDate>
          <text>Became Public Law No: 113-233.</text>
        </latestAction>
        <type>S</type>
        <congress>113</congress>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
        <latestTitle>Adding Ebola to the FDA Priority Review Voucher Program Act</latestTitle>
        <number>2917</number>
      </item>
    </relatedBills>
    <notes>
      <item>
        <links />
        <text><![CDATA[For further action, see S.2917, which became Public Law 113-233 on 12/16/2014.]]></text>
      </item>
    </notes>
    <latestAction>
      <actionDate>2014-11-21</actionDate>
      <links />
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
    <createDate>2014-11-19T05:16:15Z</createDate>
    <cosponsors>
      <item>
        <district>29</district>
        <firstName>GENE</firstName>
        <state>TX</state>
        <sponsorshipDate>2014-11-18</sponsorshipDate>
        <fullName>Rep. Green, Gene [D-TX-29]</fullName>
        <lastName>GREEN</lastName>
        <party>D</party>
        <bioguideId>G000410</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
        <middleName />
        <identifiers>
          <lisID>462</lisID>
          <bioguideId>G000410</bioguideId>
          <gpoId>8185</gpoId>
        </identifiers>
      </item>
      <item>
        <district>1</district>
        <firstName>G. K.</firstName>
        <state>NC</state>
        <sponsorshipDate>2014-11-18</sponsorshipDate>
        <fullName>Rep. Butterfield, G. K. [D-NC-1]</fullName>
        <lastName>Butterfield</lastName>
        <party>D</party>
        <bioguideId>B001251</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
        <middleName />
        <identifiers>
          <lisID>1761</lisID>
          <gpoId>8024</gpoId>
          <bioguideId>B001251</bioguideId>
        </identifiers>
      </item>
      <item>
        <district>10</district>
        <firstName>Michael</firstName>
        <state>TX</state>
        <sponsorshipDate>2014-11-18</sponsorshipDate>
        <fullName>Rep. McCaul, Michael T. [R-TX-10]</fullName>
        <lastName>McCaul</lastName>
        <party>R</party>
        <bioguideId>M001157</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
        <middleName>T.</middleName>
        <identifiers>
          <lisID>1804</lisID>
          <gpoId>8166</gpoId>
          <bioguideId>M001157</bioguideId>
        </identifiers>
      </item>
      <item>
        <district>3</district>
        <firstName>Charles</firstName>
        <state>TN</state>
        <sponsorshipDate>2014-11-18</sponsorshipDate>
        <fullName>Rep. Fleischmann, Charles J. "Chuck" [R-TN-3]</fullName>
        <lastName>Fleischmann</lastName>
        <party>R</party>
        <bioguideId>F000459</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
        <middleName>J. "Chuck"</middleName>
        <identifiers>
          <lisID>2061</lisID>
          <gpoId>8150</gpoId>
          <bioguideId>F000459</bioguideId>
        </identifiers>
      </item>
    </cosponsors>
    <originChamber>House</originChamber>
    <actions>
      <item>
        <actionDate>2014-11-21</actionDate>
        <committee>
          <systemCode>hsif14</systemCode>
          <name>Health Subcommittee</name>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <committee>
          <systemCode>hsif00</systemCode>
          <name>Energy and Commerce Committee</name>
        </committee>
        <actionDate>2014-11-18</actionDate>
        <links />
      </item>
      <item>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <committee />
        <actionDate>2014-11-18</actionDate>
        <links />
      </item>
      <item>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <committee />
        <actionDate>2014-11-18</actionDate>
        <links />
      </item>
      <actionTypeCounts>
        <introducedInTheHouse>1</introducedInTheHouse>
        <introducedInHouse>1</introducedInHouse>
        <placeholderTextForH>1</placeholderTextForH>
        <billReferrals>1</billReferrals>
      </actionTypeCounts>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
    </actions>
    <title>Adding Ebola to the FDA Priority Review Voucher Program Act</title>
    <amendments />
    <billNumber>5729</billNumber>
    <laws />
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Drug therapy</name>
          </item>
          <item>
            <name>Infectious and parasitic diseases</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <committeeReports />
    <introducedDate>2014-11-18</introducedDate>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

